UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

English Journal

Lepore M1, de Lalla C2, Gundimeda SR3, Gsellinger H3, Consonni M2, Garavaglia C2, Sansano S3, Piccolo F2, Scelfo A2, Häussinger D3, Montagna D4, Locatelli F5, Bonini C2, Bondanza A2, Forcina A2, Li Z6, Ni G6, Ciceri F2, Jenö P3, Xia C6, Mori L7, Dellabona P8, Casorati G8, De Libero G7.
The Journal of experimental medicine.J Exp Med.2014 Jun 30;211(7):1363-77. doi: 10.1084/jem.20140410. Epub 2014 Jun 16.
T cells that recognize self-lipids presented by CD1c are frequent in the peripheral blood of healthy individuals and kill transformed hematopoietic cells, but little is known about their antigen specificity and potential antileukemia effects. We report that CD1c self-reactive T cells recognize a nov
PMID 24935257

Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia.

Aldoss I1, Mark L, Vrona J, Ramezani L, Weitz I, Mohrbacher AM, Douer D.
Annals of hematology.Ann Hematol.2014 Jun 7. [Epub ahead of print]
Arsenic trioxide (ATO) is highly effective in acute promyelocytic leukemia (APL), but despite its multiple mechanism of action, it has no activity in acute myeloid leukemia (AML) that excludes APL (non-APL AML). Ascorbic acid (AA) and ATO induces apoptosis in AML cell lines by depleting intracellula
PMID 24906216

Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity.

Chan WK1, Suwannasaen D1, Throm RE2, Li Y1, Eldridge PW3, Houston J1, Gray JT2, Pui CH4, Leung W5.
Leukemia.Leukemia.2014 Jun 3. doi: 10.1038/leu.2014.174. [Epub ahead of print]
Chimeric antigen receptor (CAR)-redirected cellular therapy is an attractive modality for cancer treatment. We hypothesized that allogeneic CAR-engineered CD45RA-negative T cells can control cancer and infection without the risk of graft-versus-host disease (GVHD). We used CD19+ MLL-rearranged leuke
PMID 24888271

腫瘍抗原特異的T細胞受容体遺伝子導入を用いた遺伝子改変T細胞による抗白血病養子免疫療法 (第75回日本血液学会学術集会) -- (Symposium 4 : New paradigm of cell and molecular machineries for advanced immune therapy)

Nitto Takeaki,Sawaki Kohei
Journal of Pharmacological Sciences 126(3), 179-185, 2014
Acute promyelocytic leukemia (APL) is characterized by the occurrence of translocations between chromosomes 15 and 17, resulting in generation of a fusion protein of promyelocytic leukemia (PML) and r …
NAID 130004699218